Loading...
Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer
Lung cancer is the most common cause of cancer associated mortality. Chemotherapeutic agents, such as paclitaxel, are important treatment options but drug resistance often develops upon prolonged use. We report here the preclinical evaluation of a new orally available tubulin inhibitor, VERU-111, wh...
Saved in:
| Published in: | Cancer Lett |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7669640/ https://ncbi.nlm.nih.gov/pubmed/32920198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2020.09.004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|